UK regulatory flagship launched - without a captain:
This article was originally published in Clinica
Executive Summary
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) came into being today (April 1 2003), following the merging of the Medical Devices Agency (MDA) and the Medicines Control Agency (MCA). The DoH has not yet, however, been able to find a chief executive to lead the organisation, and there is no evidence to suggest that this will happen in the foreseeable future. The DoH would not say how close they are to being able to announce an appointment; the post was advertised in October 2002. Nor has it appointed a replacement for Alasdair Breckenridge, now chairing the MHRA board, following his departure as chairman of the Committee on Safety of Medicines (CSM).
You may also be interested in...
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.